Glanzmann’s disease, also known as Glanzmann thrombasthenia, is a rare inherited bleeding disorder that affects the way platelets function in the blood, leading to prolonged and sometimes severe bleeding episodes throughout life.

How Treatment Helps People with Glanzmann’s Disease

Treatment for Glanzmann’s disease focuses on controlling bleeding episodes when they occur and preventing excessive blood loss during situations where bleeding is expected, such as surgery, dental procedures, or childbirth. The main goal is to help people with this condition manage bleeding symptoms and maintain a good quality of life. Because Glanzmann’s disease is a lifelong disorder, treatment approaches are tailored to each person’s specific needs, the severity of their symptoms, and whether they have developed complications from previous treatments.

Medical societies and treatment centers around the world have developed guidelines based on years of experience caring for patients with this rare condition. These standard approaches work alongside ongoing research into new therapies being tested in clinical trials. Since people with Glanzmann’s disease experience different levels of bleeding—some having mild symptoms that can be managed at home, while others face severe, life-threatening episodes—treatment must be individualized and adjusted over time.

Standard Treatment Approaches

The foundation of treating Glanzmann’s disease involves both preventive strategies and active management of bleeding episodes. For many years, healthcare providers have relied on several established methods that address different aspects of the condition. The choice of treatment depends on the location and severity of bleeding, whether the person has received blood products before, and whether they have developed antibodies that make certain treatments less effective.

Platelet transfusions have traditionally been the standard treatment for severe bleeding episodes and for preventing excessive blood loss during surgery. Platelets are the tiny blood cells responsible for forming clots, and in people with Glanzmann’s disease, their own platelets cannot stick together properly because they lack a crucial protein called integrin alpha IIb/beta 3 (also known as GPIIb/IIIa). When donor platelets are transfused, they bring this missing protein and can temporarily restore the ability to form clots.^[7]

However, platelet transfusions come with significant challenges. Because the donor platelets contain the protein that people with Glanzmann’s disease naturally lack, their immune system may recognize these donated platelets as foreign. This can lead to the production of antibodies—protective proteins that attack and destroy the transfused platelets. Once antibodies develop, future platelet transfusions become less effective or may not work at all. This complication, known as alloimmunization, affects a significant number of people who receive multiple transfusions.^[7]

To reduce the risk of developing antibodies, healthcare providers use special preparation techniques. Blood products are filtered to remove white blood cells (leukocytes), a process called leukocyte depletion. Additionally, whenever possible, platelets are matched based on human leukocyte antigens (HLA), which are proteins on the surface of cells that help the immune system distinguish between the body’s own cells and foreign ones. These precautions help minimize the immune response but don’t eliminate the risk entirely.^[7]

Recombinant factor VIIa is an important treatment option that has transformed the care of people with Glanzmann’s disease, particularly those who have developed antibodies to platelets or for whom platelet transfusions are not working. This medication, marketed under the brand name NovoSeven, is a laboratory-made version of a natural clotting protein. It works by boosting the body’s clotting process at the site of bleeding, helping to form a stable clot even when platelets cannot aggregate properly.^[7]

The medication has been approved by regulatory authorities in the United States and other countries specifically for treating bleeding episodes in people with Glanzmann’s disease, whether or not they have platelet antibodies. It is also approved for preventing excessive bleeding during surgical procedures. Studies tracking its use in real-world settings, including data from the Glanzmann’s Thrombasthenia Registry involving more than 200 patients, have shown high success rates and a good safety profile. The medication can be used for both surgical and non-surgical bleeding, making it a versatile option in the treatment arsenal.^[7]

Antifibrinolytic agents, particularly tranexamic acid (sometimes referred to by the brand name Amicar or similar products), are medications that help stabilize blood clots once they form. When the body forms a clot, there are natural processes that eventually break it down. Tranexamic acid works by slowing down this breakdown process, allowing clots to remain in place longer. This medication is especially useful for bleeding from mucous membranes, such as nosebleeds, bleeding gums, or heavy menstrual bleeding. It can be taken by mouth as pills or liquid, applied directly to bleeding areas, or given through a vein, depending on the situation.^[7]

For localized bleeding that isn’t too severe, several topical treatments can be applied directly to the bleeding site. Fibrin sealants are biological glues that help wounds close and stop bleeding. Topical thrombin is another substance that can be applied to bleeding surfaces to promote clot formation. These local measures are often the first line of treatment for minor bleeds and can sometimes prevent the need for more intensive therapies.^[7]

Desmopressin (also called DDAVP) is a medication sometimes used to control less severe bleeding episodes. While its effectiveness in Glanzmann’s disease varies from person to person, some individuals may benefit from this treatment for minor bleeds.^[7]

Women and girls with Glanzmann’s disease face particular challenges related to menstruation. Heavy menstrual bleeding, medically termed menorrhagia, is extremely common and can lead to iron-deficiency anemia over time. Hormonal therapy, including birth control pills, patches, or intrauterine devices that release hormones, can significantly reduce menstrual flow and improve quality of life. These treatments work by thinning the lining of the uterus or preventing menstruation altogether, thereby reducing blood loss each month.^[11]

Supportive care is equally important in managing Glanzmann’s disease. People who experience frequent bleeding episodes often develop anemia due to ongoing blood loss. Iron supplementation and sometimes folate (a B vitamin) are prescribed to help the body replenish red blood cells and combat fatigue. Maintaining good levels of these nutrients supports overall health and helps the body recover from bleeding episodes more quickly.^[4]

Preventive measures also play a crucial role in standard care. Because people with Glanzmann’s disease may require multiple blood product transfusions throughout their lives, they face an increased risk of infections transmitted through blood. Vaccination against hepatitis B is strongly recommended to protect against this liver infection that can be spread through blood exposure. Maintaining excellent dental hygiene is another important preventive strategy, as healthy gums and teeth reduce the risk of gum bleeding, which is a common problem in this condition.^[4]

Innovative Therapies in Clinical Trials

While standard treatments have improved outcomes for many people with Glanzmann’s disease, researchers continue to explore new therapeutic approaches that could offer better control of bleeding, fewer side effects, or even a permanent cure. Clinical trials are research studies where new treatments are tested in volunteers to determine whether they are safe and effective. These studies progress through different phases, each designed to answer specific questions about the experimental therapy.

One of the most exciting areas of research involves gene therapy, which aims to correct the underlying genetic defect that causes Glanzmann’s disease. Since the condition results from mutations in either the ITGA2B or ITGB3 genes—which provide instructions for making the two parts of the integrin protein—gene therapy attempts to deliver working copies of these genes to the patient’s cells. Researchers are investigating various methods to introduce the correct genetic material into the body, potentially allowing cells to produce the missing or defective protein naturally.^[7]

This approach is still largely experimental and faces several technical challenges. Scientists must find safe and effective ways to deliver the genes specifically to the right cells, ensure that the corrected genes are expressed at appropriate levels, and prevent unwanted immune responses. While gene therapy offers the theoretical possibility of a one-time treatment that could cure the disease, it remains in early research phases and is not yet available as a standard treatment option. Studies are ongoing in specialized research centers, primarily in the United States and Europe.^[7]

Hematopoietic stem cell transplantation (HSCT), sometimes called bone marrow transplant, is another approach that could potentially cure Glanzmann’s disease. Stem cells are immature cells found in bone marrow that can develop into all types of blood cells, including platelets. In HSCT, the patient’s faulty blood-forming cells are replaced with healthy donor stem cells that carry the correct genes. If successful, these donor stem cells establish themselves in the bone marrow and begin producing normal platelets with functional integrin proteins.^[7]

While HSCT has been performed in a small number of people with severe Glanzmann’s disease, it remains controversial and is not considered a standard treatment. The procedure itself carries significant risks, including potentially life-threatening complications such as graft-versus-host disease (where the donated immune cells attack the recipient’s body), infections, and organ damage. Because of these serious risks, HSCT is typically considered only for individuals with extremely severe disease who have not responded to other treatments and who experience frequent life-threatening bleeding episodes. The procedure requires extensive preparation, including intensive chemotherapy to eliminate the patient’s existing bone marrow, followed by careful monitoring and long-term follow-up.^[7]

Researchers are also studying whether improvements to existing treatments could make them more effective or reduce side effects. This includes investigating optimal dosing strategies for recombinant factor VIIa in different bleeding scenarios, developing better ways to predict which patients will respond to specific treatments, and creating protocols to manage complications when they arise. Some clinical trials are examining combinations of treatments—for example, using tranexamic acid together with other hemostatic agents—to see if multiple therapies working together provide better bleeding control than any single treatment alone.^[8]

Clinical trials examining new approaches to preventing platelet alloimmunization are also underway. Since the development of antibodies against transfused platelets is one of the major complications limiting treatment options, finding ways to prevent or reverse this immune response would be extremely valuable. Some research focuses on techniques to induce immune tolerance, where the body is trained not to react against the donor platelets despite their foreign proteins.

In France, specialized reference centers for inherited platelet disorders have developed consensus recommendations for the emergency management of patients with Glanzmann’s disease. These guidelines, which represent expert opinion based on clinical experience and available evidence, help standardize care and ensure that people receive appropriate treatment regardless of where they seek medical attention. Similar efforts are underway in other countries to develop care protocols tailored to local healthcare systems and resources.^[12]

Most common treatment methods

• Platelet transfusions
  • Standard treatment for severe bleeding and surgical procedures
  • Provide functional platelets with the missing integrin protein
  • Must be leukocyte-depleted to reduce risk of antibody development
  • HLA-matched platelets preferred when available to minimize immune reactions
  • Risk of alloimmunization limits repeated use
• Recombinant factor VIIa
  • Approved for bleeding episodes and perioperative management
  • Effective regardless of platelet antibody status
  • Works by enhancing clot formation at bleeding sites
  • High efficacy rates with good safety profile demonstrated in registry studies
  • Can be used when platelet transfusions are ineffective
• Antifibrinolytic therapy
  • Tranexamic acid stabilizes blood clots
  • Particularly useful for mucosal bleeding including nosebleeds and gum bleeding
  • Can be given orally, topically, or intravenously
  • Often used for managing heavy menstrual bleeding
  • May be combined with other treatments
• Hormonal therapy
  • Birth control pills and other hormonal contraceptives
  • Reduces or eliminates heavy menstrual bleeding in women
  • Helps prevent iron-deficiency anemia
  • Improves quality of life for women with menorrhagia
• Local hemostatic measures
  • Fibrin sealants applied directly to bleeding sites
  • Topical thrombin for surface bleeding
  • First-line treatment for minor, localized bleeds
  • Can prevent need for more intensive therapies
• Supportive care
  • Iron supplementation to treat anemia from blood loss
  • Folate supplementation to support red blood cell production
  • Hepatitis B vaccination for infection prevention
  • Dental hygiene to reduce gum bleeding
• Experimental approaches in clinical trials
  • Gene therapy to correct the underlying genetic defect
  • Hematopoietic stem cell transplantation for severe cases
  • Studies on immune tolerance induction
  • Optimization of existing treatment protocols